These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 23624993)

  • 41. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
    Baigent C; Landray MJ; Reith C; Emberson J; Wheeler DC; Tomson C; Wanner C; Krane V; Cass A; Craig J; Neal B; Jiang L; Hooi LS; Levin A; Agodoa L; Gaziano M; Kasiske B; Walker R; Massy ZA; Feldt-Rasmussen B; Krairittichai U; Ophascharoensuk V; Fellström B; Holdaas H; Tesar V; Wiecek A; Grobbee D; de Zeeuw D; Grönhagen-Riska C; Dasgupta T; Lewis D; Herrington W; Mafham M; Majoni W; Wallendszus K; Grimm R; Pedersen T; Tobert J; Armitage J; Baxter A; Bray C; Chen Y; Chen Z; Hill M; Knott C; Parish S; Simpson D; Sleight P; Young A; Collins R;
    Lancet; 2011 Jun; 377(9784):2181-92. PubMed ID: 21663949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lixisenatide for type 2 diabetes mellitus.
    Christensen M; Knop FK; Vilsbøll T; Holst JJ
    Expert Opin Investig Drugs; 2011 Apr; 20(4):549-57. PubMed ID: 21391833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
    Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
    Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
    Abe M; Okada K; Soma M
    Curr Drug Metab; 2011 Jan; 12(1):57-69. PubMed ID: 21303332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
    Morrow L; Hompesch M; Guthrie H; Chang D; Chatterjee DJ
    Diabetes Obes Metab; 2011 Jan; 13(1):75-80. PubMed ID: 21114606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.
    Malm-Erjefält M; Bjørnsdottir I; Vanggaard J; Helleberg H; Larsen U; Oosterhuis B; van Lier JJ; Zdravkovic M; Olsen AK
    Drug Metab Dispos; 2010 Nov; 38(11):1944-53. PubMed ID: 20709939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.
    Schulz KF; Altman DG; Moher D;
    BMJ; 2010 Mar; 340():c332. PubMed ID: 20332509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.
    Jacobsen LV; Hindsberger C; Robson R; Zdravkovic M
    Br J Clin Pharmacol; 2009 Dec; 68(6):898-905. PubMed ID: 20002084
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.
    Chatterjee DJ; Khutoryansky N; Zdravkovic M; Sprenger CR; Litwin JS
    J Clin Pharmacol; 2009 Nov; 49(11):1353-62. PubMed ID: 19737980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Campbell RK
    Ann Pharmacother; 2009 Sep; 43(9):1433-44. PubMed ID: 19638470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system.
    Riveline JP; Teynie J; Belmouaz S; Franc S; Dardari D; Bauwens M; Caudwell V; Ragot S; Bridoux F; Charpentier G; Marechaud R; Hadjadj S
    Nephrol Dial Transplant; 2009 Sep; 24(9):2866-71. PubMed ID: 19389864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
    Fellström BC; Jardine AG; Schmieder RE; Holdaas H; Bannister K; Beutler J; Chae DW; Chevaile A; Cobbe SM; Grönhagen-Riska C; De Lima JJ; Lins R; Mayer G; McMahon AW; Parving HH; Remuzzi G; Samuelsson O; Sonkodi S; Sci D; Süleymanlar G; Tsakiris D; Tesar V; Todorov V; Wiecek A; Wüthrich RP; Gottlow M; Johnsson E; Zannad F;
    N Engl J Med; 2009 Apr; 360(14):1395-407. PubMed ID: 19332456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials.
    Heerspink HJ; Ninomiya T; Zoungas S; de Zeeuw D; Grobbee DE; Jardine MJ; Gallagher M; Roberts MA; Cass A; Neal B; Perkovic V
    Lancet; 2009 Mar; 373(9668):1009-15. PubMed ID: 19249092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
    Klonoff DC; Buse JB; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Wintle ME; Maggs DG
    Curr Med Res Opin; 2008 Jan; 24(1):275-86. PubMed ID: 18053320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of renal impairment on the pharmacokinetics of exenatide.
    Linnebjerg H; Kothare PA; Park S; Mace K; Reddy S; Mitchell M; Lins R
    Br J Clin Pharmacol; 2007 Sep; 64(3):317-27. PubMed ID: 17425627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study.
    Hayashino Y; Fukuhara S; Akiba T; Akizawa T; Asano Y; Saito A; Bragg-Gresham JL; Ramirez SP; Port FK; Kurokawa K
    Diabetologia; 2007 Jun; 50(6):1170-7. PubMed ID: 17393134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved survival rate in patients with diabetes and end-stage renal disease in Denmark.
    Sørensen VR; Mathiesen ER; Heaf J; Feldt-Rasmussen B
    Diabetologia; 2007 May; 50(5):922-9. PubMed ID: 17333109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.